Resultados de la búsqueda 261-270 of 17840 for B cell lymphomas
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas. Rochester, Minn. This is a Phase 1b ...
... B-cell Lymphoma (R/R DLBCL). Rochester, Minn. Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by ...
Giving rituximab together with romidepsin and lenalidomide may be a better treatment for B-cell non-Hodgkin lymphoma. A Study of Women undergoing Mammogram ...
Giving rituximab together with romidepsin and lenalidomide may be a better treatment for B-cell non-Hodgkin lymphoma. Testing the Addition of an Anti-cancer ...
... B-cell lymphoma 2 (BCL2) inhibitor. Tissue and Blood Registry for Individuals with Liver and Biliary Tumors. Jacksonville, Fla. This study will collect and ...
... B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. ... lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. ... lymphoma (B ...
... B-cell lymphoma 2 (BCL2) inhibitor. Sacituzumab Tirumotecan (MK-2870) In Combination With Pembrolizumab Versus Pembrolizumab Alone In Metastatic Non-small Cell ...
... B-cell lymphoma 2 (BCL2) inhibitor. MC1733, Phase I Trial Of Intratumoral Administration Of A Measles Virus Derivative Expressing The Helicobacter Pylori ...
... B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Testing The Addition ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?